Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Immune recognition of somatic mutations leading to complete durable regression in metastatic... Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations—such as melanoma, smoking-induced lung cancers and bladder cancer—with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary 1–7 . Adoptive transfer of autologous lymphocytes that specifically target proteins encoded by somatically mutated genes has mediated substantial objective clinical regressions in patients with metastatic bile duct, colon and cervical cancers 8–11 . We present a patient with chemorefractory hormone receptor (HR)-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes (TILs) reactive against mutant versions of four proteins—SLC3A2, KIAA0368, CADPS2 and CTSB. Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for >22 months, and it represents a new immunotherapy approach for the treatment of these patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Medicine Springer Journals

Loading next page...
 
/lp/springer_journal/immune-recognition-of-somatic-mutations-leading-to-complete-durable-LKCl7yKqTs

References (22)

  • A. Pasetto, A. Gros, P. Robbins, D. Deniger, Todd Prickett, Rodrigo Matus-Nicodemos, D. Douek, Bryan Howie, H. Robins, M. Parkhurst, J. Gartner, Kasia Trebska-Mcgowan, J. Crystal, S. Rosenberg (2016)

    Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor

    Cancer Immunology Research, 4

  • J. Aldrich (1997)

    R.A. Fisher and the making of maximum likelihood 1912-1922

    Statistical Science, 12

  • Astar Haga-Friedman, Miryam Horovitz-Fried, C. Cohen (2012)

    Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity

    The Journal of Immunology, 188

  • E. Tran, P. Robbins, Yong-Chen Lu, Todd Prickett, J. Gartner, Li Jia, A. Pasetto, Zhili Zheng, Satyajit Ray, E. Groh, Isaac Kriley, S. Rosenberg (2016)

    T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

    The New England journal of medicine, 375 23

  • C. Lefebvre, T. Bachelot, T. Filleron, Marion Pedrero, M. Campone, J. Soria, C. Massard, C. Lévy, M. Arnedos, M. Lacroix-Triki, Julie Garrabey, Y. Boursin, M. Deloger, Yu Fu, F. Commo, V. Scott, L. Lacroix, M. Dieci, M. Kamal, V. Diéras, A. Gonçalves, Jean-Marc Ferrerro, G. Romieu, L. Vanlemmens, M. Reynier, J. Thery, F. Du, S. Guiu, F. Dalenc, G. Clapisson, H. Bonnefoi, M. Jimenez, C. Tourneau, F. André (2016)

    Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

    PLoS Medicine, 13

  • D. Koboldt, R. Fulton, M. McLellan, Heather Schmidt, Joelle Kalicki-Veizer, Joshua McMichael, L. Fulton, D. Dooling, L. Ding, E. Mardis, R. Wilson, Adrian Ally, M. Balasundaram, Y. Butterfield, R. Carlsen, Candace Carter, Andy Chu, E. Chuah, Hye-Jung Chun, R. Coope, Noreen Dhalla, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, E. Pleasance, A. Robertson, J. Schein, A. Shafiei, Payal Sipahimalani, Jared Slobodan, D. Stoll, Angela Tam, N. Thiessen, R. Varhol, N. Wye, Thomas Zeng, Yongjun Zhao, I. Birol, Steven Jones, M. Marra, A. Cherniack, G. Saksena, R. Onofrio, Nam Pho, S. Carter, S. Schumacher, B. Tabak, Bryan Hernandez, Jeff Gentry, Huy Nguyen, A. Crenshaw, K. Ardlie, R. Beroukhim, W. Winckler, G. Getz, S. Gabriel, M. Meyerson, L. Chin, R. Kucherlapati, K. Hoadley, J. Auman, C. Fan, Yidi Turman, Yan Shi, Ling Li, M. Topal, Xiaping He, H. Chao, A. Prat, Grace Silva, M. Iglesia, Wei Zhao, Jerry Usary, J. Berg, Michael Adams, J. Booker, Junyuan Wu, Anisha Gulabani, T. Bodenheimer, A. Hoyle, J. Simons, Matthew Soloway, Lisle Mose, S. Jefferys, S. Balu, J. Parker, D. Hayes, C. Perou, Simeen Malik, S. Mahurkar, Hui Shen, D. Weisenberger, T. Triche, Phillip Lai, M. Bootwalla, D. Maglinte, B. Berman, D. Berg, S. Baylin, P. Laird, C. Creighton, L. Donehower, M. Noble, Douglas Voet, N. Gehlenborg, D. Cara, Juinhua Zhang, Hailei Zhang, Chang-Jiun Wu, Spring Liu, M. Lawrence, L. Zou, A. Sivachenko, Pei Lin, P. Stojanov, R. Jing, Juok Cho, Raktim Sinha, R. Park, Marc-Danie Nazaire, James Robinson, H. Thorvaldsdóttir, J. Mesirov, P. Park, Sheila Reynolds, R. Kreisberg, Brady Bernard, Ryan Bressler, Timo Erkkilä, Jake Lin, V. Thorsson, Wei Zhang, I. Shmulevich, G. Ciriello, Nils Weinhold, N. Schultz, Jianjiong Gao, E. Cerami, Benjamin Gross, A. Jacobsen, Rileen Sinha, B. Aksoy, Yevgeniy Antipin, B. Reva, R. Shen, B. Taylor, M. Ladanyi, C. Sander, Pavana Anur, P. Spellman, Yiling Lu, Wenbin Liu, R. Verhaak, G. Mills, R. Akbani, Nianxiang Zhang, B. Broom, Tod Casasent, Chris Wakefield, A. Unruh, K. Baggerly, K. Coombes, J. Weinstein, D. Haussler, C. Benz, Joshua Stuart, S. Benz, Jingchun Zhu, C. Szeto, G. Scott, C. Yau, Evan Paull, Daniel Carlin, Christopher Wong, Artem Sokolov, J. Thusberg, S. Mooney, S. Ng, Theodore Goldstein, K. Ellrott, Mia Grifford, C. Wilks, Singer Ma, Brian Craft, Chunhua Yan, Ying Hu, D. Meerzaman, J. Gastier-Foster, Jay Bowen, N. Ramirez, Aaron Black, R. Pyatt, P. White, E. Zmuda, J. Frick, T. Lichtenberg, Robin Brookens, Myra George, M. Gerken, H. Harper, K. Leraas, L. Wise, Teresa Tabler, Cynthia McAllister, T. Barr, Melissa Hart-Kothari, Katherine Tarvin, Charles Saller, G. Sandusky, Colleen Mitchell, M. Iacocca, Jennifer Brown, B. Rabeno, Christine Czerwinski, N. Petrelli, Oleg Dolzhansky, M. Abramov, Olga Voronina, O. Potapova, J. Marks, W. Suchorska, D. Murawa, W. Kycler, Matthew Ibbs, Konstanty Korski, A. Spychała, P. Murawa, Jacek Brzeziński, Hanna Perz, Radoslaw Łaźniak, M. Teresiak, Honorata Tatka, E. Leporowska, M. Bogusz-Czerniewicz, J. Malicki, A. Mackiewicz, M. Wiznerowicz, X. Le, B. Kohl, N. Tien, Richard Thorp, N. Bang, H. Sussman, Bui Phu, R. Hajek, N. Hung, H. Thang, K. Khan, R. Penny, D. Mallery, Erin Curley, C. Shelton, P. Yena, J. Ingle, F. Couch, W. Lingle, T. King, A. González-Angulo, Mary Dyer, Shuying Liu, Xiaolong Meng, Modesto Patangan, F. Waldman, H. Stoppler, W. Rathmell, L. Thorne, Meijuan Huang, L. Boice, Ashley Hill, C. Morrison, Carmelo Gaudioso, W. Bshara, K. Daily, Sophie Egea, M. Pegram, C. Gomez-Fernandez, R. Dhir, R. Bhargava, A. Brufsky, C. Shriver, J. Hooke, J. Campbell, R. Mural, Hai Hu, S. Somiari, C. Larson, B. Deyarmin, L. Kvecher, A. Kovatich, M. Ellis, T. Stricker, K. White, O. Olopade, C. Luo, Y. Chen, R. Bose, Li-Wei Chang, Andrew Beck, T. Pihl, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Zhining Wang, E. Snyder, J. Pontius, Brenda Ayala, M. Backus, Jessica Walton, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, D. Pot, Margi Sheth, John Demchok, K. Shaw, Liming Yang, G. Eley, M. Ferguson, R. Tarnuzzer, J. Zhang, Laura Dillon, K. Buetow, P. Fielding, B. Ozenberger, M. Guyer, H. Sofia, Jacqueline Palchik (2012)

    Comprehensive molecular portraits of human breast tumors

    Nature, 490

  • Jian-gang Jin, M. Sabatino, R. Somerville, J. Wilson, M. Dudley, D. Stroncek, S. Rosenberg (2012)

    Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment

    Journal of Immunotherapy, 35

  • M. Dudley, J. Yang, R. Sherry, M. Hughes, R. Royal, U. Kammula, P. Robbins, Jianping Huang, D. Citrin, S. Leitman, J. Wunderlich, N. Restifo, Armen Thomasian, Stephanie Downey, F. Smith, J. Klapper, K. Morton, C. Laurencot, D. White, S. Rosenberg (2008)

    Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 32

  • M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma Rangwala, J. Brahmer (2016)

    Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

    The New England journal of medicine, 375 19

  • E. Tran, M. Ahmadzadeh, Yong-Chen Lu, A. Gros, S. Turcotte, P. Robbins, J. Gartner, Zhili Zheng, Yong Li, Satyajit Ray, J. Wunderlich, R. Somerville, S. Rosenberg (2015)

    Immunogenicity of somatic mutations in human gastrointestinal cancers

    Science, 350

  • S. Dawood, K. Broglio, A. González-Angulo, A. Buzdar, G. Hortobagyi, S. Giordano (2008)

    Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30

  • C. Robert, A. Ribas, J. Wolchok, F. Hodi, O. Hamid, R. Kefford, R. Kefford, J. Weber, A. Joshua, W. Hwu, T. Gangadhar, A. Patnaik, R. Dronca, H. Zarour, R. Joseph, P. Boasberg, B. Chmielowski, C. Mateus, M. Postow, K. Gergich, J. Elassaiss-Schaap, Xiaoyun Li, R. Iannone, S. Ebbinghaus, S. Kang, A. Daud (2014)

    Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    The Lancet, 384

  • E. Cerami, Jianjiong Gao, U. Dogrusoz, Benjamin Gross, S. Sumer, B. Aksoy, A. Jacobsen, Caitlin Byrne, M. Heuer, E. Larsson, Yevgeniy Antipin, B. Reva, A. Goldberg, C. Sander, N. Schultz (2012)

    The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

    Cancer discovery, 2 5

  • D. Le, D. Le, J. Durham, J. Durham, Kellie Smith, Hao Wang, Bjarne Bartlett, Bjarne Bartlett, Laveet Aulakh, Laveet Aulakh, Steve Lu, Steve Lu, H. Kemberling, C. Wilt, Brandon Luber, F. Wong, F. Wong, N. Azad, A. Rucki, D. Laheru, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James Lee, T. Greten, A. Duffy, K. Ciombor, A. Eyring, B. Lam, A. Joe, S. Kang, M. Holdhoff, Ludmila Danilova, L. Cope, C. Meyer, Shibin Zhou, Shibin Zhou, R. Goldberg, D. Armstrong, K. Bever, A. Fader, J. Taube, F. Housseau, D. Spetzler, N. Xiao, D. Pardoll, N. Papadopoulos, N. Papadopoulos, K. Kinzler, K. Kinzler, J. Eshleman, B. Vogelstein, B. Vogelstein, R. Anders, R. Anders, L. Diaz, L. Diaz (2017)

    Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

    Science, 357

  • L. Alexandrov, S. Nik-Zainal, D. Wedge, S. Aparicio, S. Behjati, A. Biankin, G. Bignell, N. Bolli, Å. Borg, A. Børresen-Dale, S. Boyault, B. Burkhardt, A. Butler, C. Caldas, H. Davies, C. Desmedt, R. Eils, J. Eyfjörd, J. Foekens, M. Greaves, F. Hosoda, B. Hutter, Tomislav Ilicic, S. Imbeaud, Marcin Imielinsk, N. Jäger, David Jones, David Jones, S. Knappskog, M. Kool, S. Lakhani, C. López-Otín, Sancha Martin, N. Munshi, Hiromi Nakamura, P. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. Pearson, X. Puente, K. Raine, Manasa Ramakrishna, A. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. Schumacher, P. Span, J. Teague, Y. Totoki, A. Tutt, R. Valdés-Mas, Marit Buuren, L. Veer, A. Vincent-Salomon, N. Waddell, L. Yates, J. Zucman‐Rossi, P. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. Grimmond, R. Siebert, E. Campo, T. Shibata, S. Pfister, P. Campbell, M. Stratton (2013)

    Signatures of mutational processes in human cancer

    Nature, 500

  • J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, T. Murayama, M. Kanai, Y. Mori, S. Matsumoto, S. Chikuma, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, Akihiko Ueda, Y. Hosoe, S. Morita, M. Yokode, Akira Shimizu, T. Honjo, I. Konishi (2015)

    Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34

  • T. Powles, J. Eder, G. Fine, F. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H. Burris, D. Petrylak, S. Teng, Xiao-dong Shen, Z. Boyd, P. Hegde, Daniel Chen, N. Vogelzang (2014)

    MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Nature, 515

  • D. Abate-Daga, K. Hanada, Jeremy Davis, J. Yang, S. Rosenberg, R. Morgan (2013)

    Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.

    Blood, 122 8

  • S. Stevanović, A. Pasetto, Sarah Helman, J. Gartner, Todd Prickett, Bryan Howie, H. Robins, P. Robbins, C. Klebanoff, S. Rosenberg, C. Hinrichs (2017)

    Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer

    Science, 356

  • Y. Assadipour, N. Zacharakis, J. Crystal, Todd Prickett, J. Gartner, R. Somerville, Hui Xu, Mary Black, Li Jia, Harshini Chinnasamy, Isaac Kriley, Lily Lu, J. Wunderlich, Zhili Zheng, Yong-Chen Lu, P. Robbins, S. Rosenberg, Stephanie Goff, S. Feldman (2017)

    Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer

    Clinical Cancer Research, 23

  • E. Tran, S. Turcotte, A. Gros, P. Robbins, Yong-Chen Lu, M. Dudley, J. Wunderlich, R. Somerville, Katherine Hogan, C. Hinrichs, M. Parkhurst, J. Yang, S. Rosenberg (2014)

    Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Science, 344

  • C. Cohen, Yangbing Zhao, Zhili Zheng, S. Rosenberg, R. Morgan (2006)

    Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

    Cancer research, 66 17

Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Biomedicine; Biomedicine, general; Cancer Research; Metabolic Diseases; Infectious Diseases; Molecular Medicine; Neurosciences
ISSN
1078-8956
eISSN
1546-170X
DOI
10.1038/s41591-018-0040-8
Publisher site
See Article on Publisher Site

Abstract

Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations—such as melanoma, smoking-induced lung cancers and bladder cancer—with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary 1–7 . Adoptive transfer of autologous lymphocytes that specifically target proteins encoded by somatically mutated genes has mediated substantial objective clinical regressions in patients with metastatic bile duct, colon and cervical cancers 8–11 . We present a patient with chemorefractory hormone receptor (HR)-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes (TILs) reactive against mutant versions of four proteins—SLC3A2, KIAA0368, CADPS2 and CTSB. Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for >22 months, and it represents a new immunotherapy approach for the treatment of these patients.

Journal

Nature MedicineSpringer Journals

Published: Jun 4, 2018

There are no references for this article.